{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:19:34Z","timestamp":1790795974819,"version":"4.1.0"},"reference-count":135,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a persistent, inflammatory disease that affects individuals with psoriasis, arthritis, and enthesitis. Research has demonstrated that inflammatory cytokines such as tumor necrosis factor-alpha (TNF-\u03b1), interleukin-23 (IL-23), and interleukin-17 (IL-17) play a pivotal role in both the onset and progression of PsA. These cytokines are generated by activated immune cells and stimulate the attraction of inflammatory cells to the synovium and joint tissues, resulting in the deterioration of cartilage and bone. The blocking of these cytokines has become a successful treatment strategy for PsA, as biological drugs that inhibit TNF-\u03b1, IL-23, and IL-17 have demonstrated notable clinical benefits. The association between PsA and other types of inflammatory cytokines or chemokines, excluding TNF-\u03b1, IL-23, and IL-17, has been extensively investigated in numerous studies. These findings may provide a chance for the discovery of novel therapeutic agents targeting other molecules, distinct from the currently approved biologics and targeted synthetic disease-modifying anti-rheumatic drugs. In this review, we discuss the current understanding of the role of inflammatory cytokines in PsA pathogenesis and clinical implications of targeting these cytokines for PsA treatment.<\/jats:p>","DOI":"10.3390\/ijms241411662","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T21:20:14Z","timestamp":1689801614000},"page":"11662","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5894-9305","authenticated-orcid":false,"given":"Bong-Woo","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7338-0652","authenticated-orcid":false,"given":"Su-Jin","family":"Moon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Yeouido St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 07345, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e001450","DOI":"10.1136\/rmdopen-2020-001450","article-title":"Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: Results of the worldwide, cross-sectional ASAS-PerSpA study","volume":"7","author":"Molto","year":"2021","journal-title":"RMD Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"681172","DOI":"10.3389\/fmed.2021.681172","article-title":"Psoriasis to Psoriatic Arthritis: The Application of Proteomics Technologies","volume":"8","author":"Qi","year":"2021","journal-title":"Front. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6\u2005months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/rheumatology\/kev296","article-title":"HLA-B27 and psoriatic disease: A modern view of an old relationship","volume":"55","author":"Queiro","year":"2016","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1399-0039.1996.tb02687.x","article-title":"Significance of antibodies to streptococcal M protein in psoriatic arthritis and their association with HLA-A*0207","volume":"48","author":"Muto","year":"1996","journal-title":"Tissue Antigens."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/annrheumdis-2016-209334","article-title":"Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis","volume":"76","author":"Thorarensen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","first-page":"507","article-title":"Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin","volume":"82","author":"Badri","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41584-020-00507-9","article-title":"Applying precision medicine to unmet clinical needs in psoriatic disease","volume":"16","author":"Jadon","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: An autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23","author":"McGonagle","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Azuaga, A.B., Ram\u00edrez, J., and Ca\u00f1ete, J.D. (2023). Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054901"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/ar2580","article-title":"Psoriatic arthritis: From pathogenesis to therapy","volume":"11","author":"Fitzgerald","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","first-page":"374","article-title":"Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: A pathogenic role for innate immunity?","volume":"34","author":"Candia","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/ar1864","article-title":"Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis","volume":"8","author":"Jongbloed","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2004.03.006","article-title":"Psoriasis vulgaris: Cutaneous lymphoid tissue supports T-cell activation and \u201cType 1\u201d inflammatory gene expression","volume":"25","author":"Lew","year":"2004","journal-title":"Trends Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.40581","article-title":"Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses","volume":"70","author":"Menegatti","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/eji.202048690","article-title":"TLR7 endogenous ligands remodel glycolytic macrophages and trigger skin-to-joint crosstalk in psoriatic arthritis","volume":"51","author":"Umar","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3523642","DOI":"10.1155\/2018\/3523642","article-title":"Involvement of M1 Macrophage Polarization in Endosomal Toll-Like Receptors Activated Psoriatic Inflammation","volume":"2018","author":"Lu","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/art.24406","article-title":"Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis","volume":"60","author":"Vandooren","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1446","article-title":"Mast cells in inflammatory arthritis","volume":"7","author":"Nigrovic","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/key331","article-title":"Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content","volume":"58","author":"Chen","year":"2019","journal-title":"Rheumatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.39261","article-title":"Brief report: Enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid","volume":"67","author":"Leijten","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2016.09.015","article-title":"Are psoriasis and psoriatic arthritis the same disease? The IL-23\/IL-17 axis data","volume":"16","author":"Sakkas","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tang, F., Sally, B., Ciszewski, C., Abadie, V., Curran, S.A., Groh, V., Fitzgerald, O., Winchester, R.J., and Jabri, B. (2013). Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076292"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"968549","DOI":"10.1155\/2013\/968549","article-title":"Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases","volume":"2013","author":"Qu","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.2854","article-title":"Primed for inflammation: Enthesis-resident T cells","volume":"18","author":"Lories","year":"2012","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"ii26","DOI":"10.1136\/ard.2004.031740","article-title":"Immunopathology of psoriasis and psoriatic arthritis","volume":"64","author":"Veale","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.autrev.2014.11.012","article-title":"T cell responses in psoriasis and psoriatic arthritis","volume":"14","author":"Diani","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/imm.12142","article-title":"Interleukin-17A: A unique pathway in immune-mediated diseases: Psoriasis, psoriatic arthritis and rheumatoid arthritis","volume":"141","author":"Kirkham","year":"2014","journal-title":"Immunology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3899\/jrheum.110283","article-title":"CD4+CD25(high)CD127(low\/-) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis","volume":"38","author":"Kawashiri","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5021\/ad.2010.22.4.397","article-title":"Role of CD4CD25FOXP3 Regulatory T Cells in Psoriasis","volume":"22","author":"Yun","year":"2010","journal-title":"Ann. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12967-019-1965-5","article-title":"Identification of novel inhibitors for TNF\u03b1, TNFR1 and TNF\u03b1-TNFR1 complex using pharmacophore-based approaches","volume":"17","author":"Saddala","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"591365","DOI":"10.3389\/fimmu.2020.591365","article-title":"Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both?","volume":"11","author":"Zamri","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fimmu.2019.00505","article-title":"What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss?","volume":"10","author":"Kamradt","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e20200288","DOI":"10.1084\/jem.20200288","article-title":"Transmembrane TNF drives osteoproliferative joint inflammation reminiscent of human spondyloarthritis","volume":"217","author":"Kaaij","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"672515","DOI":"10.3389\/fphar.2021.672515","article-title":"From Bed to Bench and Back: TNF-\u03b1, IL-23\/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis","volume":"12","author":"Silvagni","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4049\/jimmunol.1001001","article-title":"IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A","volume":"186","author":"Rizzo","year":"2011","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"iv16","DOI":"10.1093\/rheumatology\/keab385","article-title":"Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints","volume":"60","author":"Gracey","year":"2021","journal-title":"Rheumatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/rheumatology\/keab461","article-title":"Interleukin-23 in perspective","volume":"60","author":"Sherlock","year":"2021","journal-title":"Rheumatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1038\/s41598-020-65269-6","article-title":"Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice","volume":"10","author":"Chen","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"154855","DOI":"10.1016\/j.cyto.2019.154855","article-title":"Functional significance of MAIT cells in psoriatic arthritis","volume":"125","author":"Raychaudhuri","year":"2020","journal-title":"Cytokine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/rheumatology\/keu237","article-title":"Psoriatic arthritis: Current therapy and future approaches","volume":"54","author":"Huynh","year":"2015","journal-title":"Rheumatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"539683","DOI":"10.1155\/2012\/539683","article-title":"The Th17\/IL-23 Axis and Natural Immunity in Psoriatic Arthritis","volume":"2012","author":"Maeda","year":"2012","journal-title":"Int. J. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11926-022-01084-4","article-title":"Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms","volume":"24","author":"Tam","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"20406223211037846","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27149","DOI":"10.1038\/srep27149","article-title":"IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy","volume":"6","author":"Millar","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: Recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23\u2013IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-022-02771-4","article-title":"Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: A retrospective study","volume":"24","author":"Miyagawa","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13075-020-02315-8","article-title":"Interleukin (IL)-25 suppresses IL-22-induced osteoclastogenesis in rheumatoid arthritis via STAT3 and p38 MAPK\/I\u03baB\u03b1 pathway","volume":"22","author":"Min","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4049\/jimmunol.204.Supp.73.7","article-title":"IL-22 Effects on Osteoblast Mineralization and Metabolic Profile","volume":"204","author":"Holt","year":"2020","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1140373","DOI":"10.3389\/fimmu.2023.1140373","article-title":"Interleukin-32 as a biomarker in rheumatic diseases: A narrative review","volume":"14","author":"Kwon","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_68","first-page":"29","article-title":"Functional role of human interleukin-32 and nuclear transcription factor-kB in patients with psoriasis and psoriatic arthritis","volume":"12","author":"Farhan","year":"2018","journal-title":"Int. J. Health Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"739489","DOI":"10.3389\/fmed.2021.739489","article-title":"IL-33 in Rheumatic Diseases","volume":"8","author":"Dong","year":"2021","journal-title":"Front. Med."},{"key":"ref_70","first-page":"7158014","article-title":"Possible Roles of IL-33 in the Innate-Adaptive Immune Crosstalk of Psoriasis Pathogenesis","volume":"2019","author":"Bertino","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000471798","article-title":"New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions","volume":"233","author":"Li","year":"2017","journal-title":"Dermatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13075-020-2111-8","article-title":"A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations","volume":"22","author":"Sokolova","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jocd.12994","article-title":"Evaluation of the expression of the stromal cell-derived factor-1 alpha (CXCL 12) in psoriatic patients after treatment with Methotrexate","volume":"19","author":"Abdelaal","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2021-220280","article-title":"Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid","volume":"80","author":"Yager","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","first-page":"486","article-title":"Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis","volume":"36","author":"Abji","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/eji.201747195","article-title":"CXCL4 is a novel inducer of human Th17 cells and correlates with IL-17 and IL-22 in psoriatic arthritis","volume":"48","author":"Affandi","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Sundanum, S., Orr, C., and Veale, D. (2023). Targeted Therapies in Psoriatic Arthritis-An Update. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076384"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: An analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.rdc.2012.08.003","article-title":"Pathophysiology of new bone formation and ankylosis in spondyloarthritis","volume":"38","author":"Lories","year":"2012","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: Results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: Results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keac353","article-title":"Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: Results from BE ACTIVE","volume":"62","author":"Mease","year":"2023","journal-title":"Rheumatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: Results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: Results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2012-304154","article-title":"Secukinumab failure in Crohn\u2019s disease: The yeast connection?","volume":"62","author":"Colombel","year":"2013","journal-title":"Gut"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/msc.1694","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","volume":"20","author":"Fragoulis","year":"2022","journal-title":"Musculoskeletal. Care"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","article-title":"Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.22645","article-title":"Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2021-221640","article-title":"Persistence and effectiveness of the IL-12\/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study","volume":"81","author":"Gossec","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: Results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Laura","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two\u2009Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e001679","DOI":"10.1136\/rmdopen-2021-001679","article-title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: Results from phase 3 trials","volume":"7","author":"Sweet","year":"2021","journal-title":"RMD Open"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Mauro","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Andrew","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: Results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Philip","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: A post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"102902","DOI":"10.1016\/j.autrev.2021.102902","article-title":"JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis","volume":"20","author":"Campanaro","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: Patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40744-021-00305-z","article-title":"Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study","volume":"8","author":"Mease","year":"2021","journal-title":"Rheumatol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cts.13146","article-title":"Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients\u2014Analyses of phase III clinical trials","volume":"15","author":"Muensterman","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e001838","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Philip","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Baraliakos","year":"2018","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s12325-022-02168-4","article-title":"MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases","volume":"39","author":"Hellstrom","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543784.2023.2207737","article-title":"Recent developments for new investigational JAK inhibitors in psoriatic arthritis","volume":"32","author":"Caso","year":"2023","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Mease, P., Helliwell, P., Silwinska-Stanczyk, P., Miakisz, M., Ostor, A., Peeva, E., Vincent, M.S., Sun, Q., Sikirica, V., and Winnette, R. (2023). Efficacy and Safety of Tyrosine Kinase 2\/Janus Kinase 1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis Rheumatol., Online ahead of print.","DOI":"10.1002\/art.42519"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial","volume":"43","author":"Maurizio","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: A phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Christopher","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: Results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2013-204934","article-title":"Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?","volume":"73","author":"Orr","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/IJN.S297631","article-title":"Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy","volume":"16","author":"Sun","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","article-title":"Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial","volume":"11","author":"Puig","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: A multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11662\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:15:07Z","timestamp":1760127307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":135,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411662"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411662","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}